Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Marios Adamou has a total of 214 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Orexin receptor antagonists for sleep disturbance in attention-deficit/hyperactivity disorder and autism spectrum disorder: a systematic review

    by Marios Adamou, Christos Petrou

    Background: Sleep disturbance is among the commonest and most impairing comorbidities of attention-deficit/hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). Melatonin has the strongest evidence base, but its action is chronobiotic, its maintenance effect inconsistent, and adult evidence sparse. Orexin receptor antagonists reduce wake drive rather than induce sedation, a mechanistically distinct alternative. Methods: Reported in accordance with PRISMA 2020. PubMed, Europe PMC, OpenAlex and ClinicalTrials.gov were searched on 23 September 2026 using three complementary concept searches with backward citation tracking; Embase and PsycINFO were not searched. Screening applied a mechanical rule, and every candidate was assessed at full text by two independent reviewers. Eligible reports described a person with diagnosed ADHD or ASD given an orexin receptor antagonist, with a sleep, behavioural, cognitive or safety outcome. Risk of bias was appraised at domain level and certainty against the GRADE domains without categorical ratings. Pooling was precluded by heterogeneity and by the absence of comparable controlled effect estimates. Results: Eight reports representing seven patient groups described 41 exposed participants, 25 with ADHD and 16 with ASD. No completed trial provides peer-reviewed or registry-posted diagnosis-specific outcomes. The strongest signal is a one-month open-label study of daridorexant 50 mg in 24 adults with ADHD and insomnia, where median insomnia severity fell from 16 to 8 and actigraphic total sleep time rose by about 24 minutes, both surviving correction, and 62.5% responded; no cognitive outcome survived correction, one worsened, and the favourable attention results required excluding sleep non-responders. In ASD the evidence is case reports and small series confounded by co-medication, the only comparison-group report being null. No report provides ADHD-stratified paediatric outcomes. Of two registered trials one is recruiting and one completed, the latter’s sponsor releasing top-line data without diagnosis-stratified outcomes. Conclusion: Orexin receptor antagonism is a mechanistically coherent approach to sleep disturbance in ADHD and ASD, but no appraisable, diagnosis-specific controlled evidence supports its use, and the evidence is too sparse and biased for causal inference. The signal that sleep gains may accompany attention gains requires a randomised test. Routine use cannot be recommended, and off-label prescribing requires individualised specialist assessment.

  • Open Access

    De-diagnosis and the problem of revisability in adult ADHD and autism

    by Marios Adamou, Darren Hill

    Recorded diagnoses of attention-deficit/hyperactivity disorder (ADHD) and autism in adults have risen sharply across high-income health systems, and demand for assessment has risen faster still, while the best available population estimates of prevalence appear to have moved comparatively little. This paper treats that divergence as an analytic problem. We argue that adult neurodevelopmental diagnosis has undergone a threefold transformation: it has become demand-led and co-produced rather than professionally imposed, identity-conferring rather than merely descriptive, and self-reinforcing rather than static. The result is a diagnostic culture efficient at conferring diagnoses but weak, unsystematic and largely untheorised in reconsidering them. Drawing on the sociology of diagnosis, labelling theory, Ian Hacking’s account of interactive kinds and discourse-analytic studies of diagnostic contestation, we examine how demand-led medicalisation, the reframing of diagnosis as valued identity and the expansive use of the camouflaging construct can impede revision in practice. Against this background we develop the concept of diagnostic revisability: the capacity of a diagnostic culture to reconsider a diagnostic judgement, in either direction, in the light of change in the person or in the evidence. We distinguish correction of an insecure original judgement, revision in response to change, supersession and reversal of a non-diagnosis, and argue that revisability is an intrinsic property of diagnosis understood as defeasible inference. Precedents exist in medication review and deprescribing and in diagnostic de-labelling elsewhere in medicine. The case is stronger for ADHD, where symptoms and diagnostic status fluctuate and diagnosis is linked to prescribing, than for autism, where it rests principally on the security of the original assessment. Recent Swedish proposals for de-diagnosis services make revisability visible as an object of policy, but the conceptual case does not itself entail support for any service model. Diagnostic revision may correct error; it may also threaten identity, access to support and self-understanding, fall unequally on particular groups, or become a mechanism for rationing. If revisability is translated into practice, it must therefore satisfy stringent ethical and institutional safeguards, including an explicit equity criterion. The design requirements presented are minimum conditions for responsible revision and criteria for when it should not proceed.

  • Open Access

    Self-medication of attention-deficit/hyperactivity disorder symptoms with psychoactive substances in adults: a scoping review of how symptom-relief motives are framed and operationalised across substances

    by Marios Adamou, Christos Petrou

    Introduction: Adults with attention-deficit/hyperactivity disorder (ADHD) use tobacco, cannabis, alcohol, cocaine and non-prescribed stimulants far more than the general population. The self-medication hypothesis holds that people with ADHD, including those undiagnosed, use substances to relieve core symptoms rather than for recreation or shared vulnerability to addiction, and is widely invoked to reframe illicit substance use as undiagnosed ADHD. How this claim is framed and tested has not been mapped across substances. Objective: To map the literature invoking self-medication of ADHD symptoms in adults, substance by substance, and to characterise how each source frames the concept relative to misuse, recreational or shared-liability accounts. Eligibility criteria: Empirical studies, reviews, commentaries, preprints and trial-register records on self-medication of ADHD symptoms with a psychoactive substance in adults or predominantly adult samples; English; inception to 21 July 2026. Information sources: PubMed, OpenAlex and Consensus, with ClinicalTrials.gov and a preprint search. Searches were conditioned on self-medication and motive terminology, so the corpus maps the self-medication literature and does not sample the misuse or shared-liability literature independently. Charting methods: Sources were charted for substance, design, population, operationalisation of self-medication, and a framing category (self-medication-framed; mixed; misuse- or shared-liability-framed; neutral/descriptive). A descriptive map was built by substance. No critical appraisal or evidence-strength ranking was made. Results: Of 937 records identified and 820 screened, 109 sources (1986–2026) met the criteria. Coverage was heaviest for non-prescribed stimulants (n=35), cannabis (n=29), nicotine (n=25) and alcohol (n=17); no eligible ketamine source was identified. Self-medication framing was most prevalent, and uniquely accompanied by experimental data, for nicotine; prevalent but observational for cannabis; coexisted with academic and recreational motives for stimulants; and alcohol was mostly framed as comorbidity or shared liability. Self-medication was overwhelmingly inferred from association or motive report rather than tested against symptom change. Conclusions: Self-medication framing is substance-specific in prevalence and accompanying evidence. Because the search was conditioned on self-medication terminology, the map describes how the literature frames the claim and does not adjudicate between competing accounts. Applying self-medication as a blanket explanation for substance use in people with ADHD symptoms is not warranted by how the claim has been tested.

  • Open Access

    Cost-consequence analysis of a criterion-based screening and triage pathway compared with full ADHD assessment for adults referred to NHS secondary care

    by Marios Adamou, Ellen Wright

    Background: National evidence indicates that attention-deficit hyperactivity disorder (ADHD) referrals, recorded diagnoses and waiting lists have increased substantially. The Comprehensive ADHD Screening Questionnaire (CASQ), a criterion-based tool delivered by trained Band 7 clinicians, achieved 100% sensitivity, with a 95% confidence interval of 61.0–100.0%, while screening out 39.6% of referrals in a prospective NHS validation study of 48 participants. This analysis compares the costs and diagnostic consequences of the CASQ-first pathway with full ADHD assessment from the NHS perspective. Methods: A prospective observational study-based cost-consequence analysis was conducted from the NHS perspective over a one-year time horizon, following the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022. A non-inferiority margin of −10 percentage points, corresponding to sensitivity of at least 90%, was specified to assess diagnostic safety. The CASQ assessment-and-triage cost was £120.27 per referral, derived bottom-up from Personal Social Services Research Unit (PSSRU) 2024 unit costs. The standard or low-complexity full ADHD assessment cost was £850, taken from the final NHS England 2026/27 Adult ADHD Assessment, Face-to-Face guide price. The weighted-mean full ADHD assessment cost was calculated using South West Yorkshire Partnership Teaching NHS Foundation Trust (SWYPFT) case-mix proportions from a previous explainable clustering analysis, giving £1, 011.28 per referral. Sensitivity analyses examined alternative cost assumptions, proportion screened out, CASQ duration and incremental clinical time for more complex full ADHD assessment cases. An expanded structural probabilistic sensitivity analysis with 10, 000 Monte Carlo simulations separately propagated uncertainty in complexity-cluster proportions, incremental Band 7 clinical hours, CASQ assessment-and-triage cost, standard full ADHD assessment cost, Band 7 hourly cost and diagnostic accuracy parameters. Results: The CASQ achieved 100% sensitivity and 100% negative predictive value in the validation study. In the SWYPFT case-mix weighted-mean base case, the CASQ-first pathway cost £731.08 per referral compared with £1, 011.28 for universal full ADHD assessment, a saving of £280.20 per referral and £598, 507 annually at 2, 136 referrals. In commissioning terms, this corresponds to an estimated saving of approximately £280, 200 for every 1, 000 referrals managed through the CASQ-first pathway under the SWYPFT case-mix weighted base case. In the expanded structural probabilistic sensitivity analysis, the CASQ-first pathway was cost-saving in 100.0% of 10, 000 simulations, with a mean saving of £285.18 per referral and £609, 143 annually at 2, 136 referrals. CASQ sensitivity met the specified 90% sensitivity threshold in 75.0% of simulations. The mean projected false-negative rate was 9.4 per 1, 000 referrals. Conclusion: The CASQ-first pathway may reduce assessment costs and redirect a substantial proportion of referrals away from a direct full ADHD assessment, but the present validation study is not adequately powered to support a definitive economic conclusion. Because the economic result rests on a sensitivity estimate derived from only six confirmed ADHD cases, the projected per-referral and national savings are illustrative planning estimates and not established savings. The economic estimates presented here are preliminary and conditional and should be regarded as a commissioning planning aid that becomes interpretable only when independent multi-site validation has established a reliable diagnostic safety margin. Decision-makers should weigh the estimated per-referral cost reduction against diagnostic accuracy uncertainty and potential harm to missed cases. Independent multi-site replication with formal non-inferiority testing is required before unconditional cost-minimisation conclusions can be drawn.

  • Open Access

    Adult ADHD diagnostic pathways in the United Kingdom: a structured review and policy case for a national commissioning and quality framework for England

    by Marios Adamou, Sarah L. Jones

    Background: Adult attention-deficit hyperactivity disorder (ADHD) diagnostic pathways in England are under sustained pressure. Demand has risen, waiting times have lengthened, service models remain fragmented, workforce capacity is uneven, and access and quality vary markedly between localities. Although the core clinical principles of ADHD diagnosis are relatively well established, the organisational conditions needed to deliver them consistently remain less secure. Aim: To synthesise UK-wide evidence on adult ADHD diagnostic pathways and to develop an evidence-informed policy case for a national commissioning and quality framework for England. Design and setting: PRISMA-informed structured policy-oriented review of UK-wide evidence on adult ADHD diagnostic pathways, interpreted through a health services and commissioning lens. The review is not a registered systematic review and did not undertake formal risk-of-bias scoring; appraisal was structured and narrative. Method: A structured literature search was conducted across PubMed/MEDLINE, Scopus, Web of Science, ScienceDirect, SpringerLink, Google Scholar, SciSpace, and ArXiv. Searches were conducted between 2023 and March 2026, focusing on publications from 2010 onwards. Screening and reporting were informed by PRISMA 2020 guidance, adapted for a structured literature review rather than a full systematic review. Eligible sources included peer-reviewed empirical studies, clinical audits, service assessments, mixed-methods studies, qualitative studies, consensus statements, systematic or scoping reviews, and policy documents relevant to adult ADHD diagnostic pathways in UK healthcare settings. Findings were synthesised thematically into pathways and cross-cutting system factors. Results: Twenty-six sources met the eligibility criteria. The evidence showed marked variation in access routes, referral quality, screening and triage practice, assessment delivery, service configuration, transition arrangements, post-diagnostic interfaces, and supporting infrastructure. Clinical standards for diagnosis were comparatively stable across NICE, the Royal College of Psychiatrists, the UK Adult ADHD Network, and the British Association for Psychopharmacology guidance, yet operational delivery was inconsistent. Policy implication: England requires a national adult ADHD commissioning and quality framework that defines minimum diagnostic standards, core pathway functions, stratified allocation of expertise, mixed-provider governance, and whole-pathway outcome monitoring. The framework proposed here is conceptual rather than operational: it defines minimum functions, standards, and governance expectations, but it does not yet specify operational criteria for stratification, complexity thresholds, audit mechanisms, or rules for local implementation, which remain matters for the implementation phase.


  • Camouflaging in autism as a dual-normative construct: a philosophical critique

    by Marios Adamou, Athanasios Koutsoklenis

    Social camouflaging—broadly defined as the suppression or modulation of autistic traits to conform to dominant ableist social norms—has become a dominant construct in autism research. Yet despite its empirical and cultural prominence, the concept has not undergone sustained philosophical scrutiny. This paper develops a fourfold critique. Ontologically, camouflaging lacks stability, as it fails to identify a coherent class of phenomena distinguishable from adjacent behaviours. Epistemologically, it relies on theory-laden and circular methodologies that presuppose what they purport to measure. Logically, it embeds contradictions, particularly in attributing intentional capacities to subjects diagnosed in part on the basis of impaired social reasoning. Ethically, it operates within a dual-normative framework that pathologises deviation while privileging narrow forms of autistic legibility. We argue that deconstructing camouflaging exposes its fragility and raises fundamental questions about the normative commitments underlying psychiatric classification.


  • Open Access

    Comparative analysis of diagnostic expectations between adults referred for ADHD and autism assessment: a thematic analysis

    by Marios Adamou, Lydia Wharton

    Background: Recent trends in neurodevelopmental services promote joint assessment pathways combining ADHD and Autism services. However, no study has systematically compared diagnostic expectations between adults seeking ADHD versus Autism assessment. Methods: This comparative qualitative study analysed expectations from 100 adults referred for ADHD assessment, comparing findings with published Autism data (n=60) from the same Trust. Both samples were of adults referred for assessment rather than diagnostically confirmed cohorts. Two open-ended questions during face-to-face appointments: “What do you hope to gain from the assessment?” and “How do you think receiving a diagnosis would help you?” ADHD responses underwent reflexive thematic analysis using Braun and Clarke’s six-phase framework, with comparison against published Autism themes. Results: Analysis revealed fundamentally divergent expectation patterns organised around contrasting meta-themes: “Seeking Legitimisation and Practical Solutions” (ADHD) versus “Understanding Self and Explaining Difference” (Autism). Five conceptual dichotomies distinguished pathways: (1) pharmacological versus psychosocial intervention paradigms (47% ADHD mentioned medication versus 1.7% Autism); (2) diagnostic certainty versus depth of understanding (31% ADHD versus 75% Autism seeking understanding); (3) passive hope for understanding versus active educator positioning (3% ADHD versus 63% Autism expecting to explain to others); (4) deficit versus difference self-concepts (15% ADHD used harsh self-descriptors versus 1.7% Autism); (5) internal overwhelm versus social-environmental mismatch phenomenology (10% ADHD described “racing mind” versus 0% Autism). These differences persisted across demographic subgroups. Conclusions: Adults seeking ADHD versus Autism assessment hold fundamentally different expectations requiring differentiated clinical responses. Findings provide empirical evidence for separate rather than combined diagnostic pathways, with condition-specific pre-assessment counselling, post-diagnostic support, and clinical expertise development. Generic ‘neurodevelopmental’ provision risks meeting no one’s actual needs.


  • Open Access

    Beyond Feedback: A Rhetorical Analysis of Not-Upheld Complaints in Adult Neurodevelopmental Assessment

    by Marios Adamou, Niki Kyriakidou, Sarah Lobley

    Objective: To analyse the rhetorical strategies employed in formal complaints regarding adult Attention Deficit Hyperactivity Disorder and Autism assessments, specifically where no service failure was identified. Methods: A rhetorical analysis was conducted on 48 complaints determined to be not upheld overall, submitted to a UK NHS Trust between 2024 and 2025. Results: Complainants demonstrated high rhetorical sophistication, frequently deploying a “Triple Core” strategy: Causal Attribution (blaming the service for life failures), Emotional Impact Description (framing dissatisfaction as medical trauma), and Procedural Challenge (alleging administrative breach). A minority (18.8%) employed economic arguments, whilst 81.2% included specific outcome demands, such as a prescription or a specific diagnosis. Conclusions: Complaints in this area of clinical practice demonstrate sophisticated rhetorical construction, functioning as instruments of organisational pressure. The “Triple Core” strategy creates an epistemic conflict where clinical judgement is contested by the patient’s lived experience narrative. These findings suggest that high complaint volumes may reflect a systemic gap between public expectation and clinical criteria rather than safety failures.


  • Open Access

    A multi-scale mathematical framework for modelling the dynamic nature of autism spectrum disorder symptoms: integrating predictive coding, information theory, and network principles

    by Marios Adamou, Athanasios Kehagias, Grigoris Antoniou

    Background: Autism Spectrum Disorder (ASD) is characterised by persistent deficits in social communication and interaction alongside restricted, repetitive patterns of behaviour, interests, or activities. Standard diagnostic criteria provide static descriptions, failing to capture the dynamic variability of these symptoms across contexts and developmental trajectories. Furthermore, current descriptions often lack mechanistic explanations for why these symptom fluctuations occur. There is a need for dynamic, theory-driven models that bridge neurobiological mechanisms with observable clinical phenomena. Objective: This study aimed to develop and present a set of interpretable mathematical models representing the dynamic, context-dependent nature of the core symptoms of ASD, explicitly grounded in established neuropsychological theories including Predictive Coding, Information Theory, and Network Neuroscience principles. Methods: Mathematical models were theoretically derived using algebraic and differential equations to represent hypothetical symptom dynamics across both diagnostic domains. Social reciprocity was modelled using modulated exponential decay functions derived from executive function and predictive processing theories. Nonverbal communication was represented by weighted summation reflecting multi-channel integration demands. Relationship development was modelled using sigmoid growth functions incorporating social motivation theory. Stereotyped movements were represented by sinusoidal functions conceptualised as homeostatic entropy-reduction mechanisms. Insistence on sameness was modelled using sigmoid preference functions explicitly derived from Bayesian precision-weighting of prediction errors. Restricted interests were represented by exponential functions reflecting atypical reward processing. Sensory sensitivities were modelled using integral functions representing habituation failure due to excitation-inhibition imbalance. No empirical data were collected; parameter ranges were derived from theoretical considerations and existing literature. Results: The study produced theoretical mathematical equations that quantify the temporal dynamics and contextual modulation for each core symptom domain. These equations provide a formalised representation grounded in mechanistic principles: how social reciprocity would decay due to executive and predictive processing load, how nonverbal communication effectiveness would depend on multi-channel integration capacity, how relationships would develop under constraints of social motivation, how repetitive behaviours would fluctuate to regulate environmental entropy, how preference for sameness would emerge from aberrant Bayesian precision, how restricted interests would persist due to heightened reward salience, and how sensory sensitivities would accumulate due to habituation failure. These models generate testable quantitative predictions about symptom patterns and intervention effects. Conclusion: The proposed mathematical models offer a novel, quantitative framework for understanding and representing the dynamic nature of ASD symptoms. By integrating mechanistic neurobiological theories with dynamic mathematical formulations, these interpretable models provide a potential advance over static descriptions and may facilitate improved clinical assessment, identification of intervention targets at the parameter level, personalised treatment strategies, and targeted research into the mechanisms underlying ASD. The framework respects neurodiversity by conceptualising many symptoms as adaptive responses to neurobiological differences rather than mere deficits. Empirical validation is required to test model predictions, estimate actual parameter values from clinical populations, and establish clinical utility.